Delek US director sells shares under trading plan
Delek US Holdings director Zohar Shlomo sold 7,343 shares of common stock in an open-market transaction at $46.00 per share.
Rhea-AI Filing Summary
Delek US Holdings director Zohar Shlomo sold 7,343 shares of common stock in an open-market transaction at $46.00 per share. The sale occurred on March 19, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Shlomo directly holds 6,646 Delek US shares.
Positive
- None.
Negative
- None.
Insights
Pre-planned director share sale, modest in scale and routine in nature.
Director Zohar Shlomo sold 7,343 shares of Delek US Holdings common stock at $46.00 per share in an open-market transaction. Following the sale, he directly owns 6,646 shares, indicating he maintains a continuing equity stake.
The transaction was made pursuant to a Rule 10b5-1 trading plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions. Such plans are set up in advance, so the timing generally reflects pre-planned diversification or liquidity rather than a new view on the company.
There were no derivative exercises or tax-withholding events disclosed in this filing, and the derivative position table is empty. Overall, this appears to be a routine, pre-planned sale with limited informational value for assessing Delek US’s underlying business performance.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,343 | $46.00 | $338K |
Footnotes (1)
- F1. This transaction was made pursuant to a 10b5-1 plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
FAQ
What did Delek US (DK) director Zohar Shlomo do in this Form 4?
Is this Delek US (DK) Form 4 a buy or sell signal from the insider?
Did the Delek US (DK) director exercise any options in this Form 4 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.